Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Prostate. 2014 Jul 22;74(13):1308–1319. doi: 10.1002/pros.22847

Figure 2.

Figure 2

Pharmacokinetics of FAP-selective prodrug activation in plasma from tumor-bearing hosts. (A)The half-life (t1/2) of the full-length FAP-activated ERGETGP-S12ADT prodrug and D-isomer control in mouse plasma is ~4–5 hrs after reaching a peak concentration (Cmax) of 35–40 µM in vivo. (B) Production of the active form of the drug from the full-length ERGETGP-S12ADT prodrug in mouse plasma in vivo. Less than 1% of the prodrug is converted to the active form in plasma. The total active drug produced includes both the S12ADTand 12ADT forms. (C) Production of the active form of the drug from the non-FAP cleavable ERGETGp-S12ADT D-isomer control. S12ADT was not generated; however, low levels of 12ADT were detected (<0.01% of total administered dose). Error bars represent +/− standard error.

HHS Vulnerability Disclosure